TITLE

Ophthotech Gets $30M Series B for Trials of Lucentis Add-Ons

AUTHOR(S)
Morrison, Trista
PUB. DATE
December 2009
SOURCE
BioWorld Today;12/15/2009, Vol. 20 Issue 240, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the 30 million U.S. dollar Series B financing secured by Ophtotech Corp. The financing round is designed to support the clinical trials of the company's age-related macular degeneration (AMD) drugs. Samir Patel, president and chief executive officer (CEO) of Ophthotech, relates the sales posted by Lucentis AMD drug in 2008. Patel highlights problem with the Lucentis AMD drug from Genentech and Roche. It outlines the results of the trial for E10030, the lead AMD drug from Ophthotech.
ACCESSION #
47122752

 

Related Articles

  • Ophthotech Gets $30M for Trials of Lucentis Add-Ons.  // Bioworld Week;12/21/2009, Vol. 17 Issue 51, p3 

    The article reports that Ophthotech Corp. has closed the 30 million dollars Series B financing round to support the clinical trials of age-related macular degeneration (AMD) drugs. Ophthotech president Samir Patel has revealed the success of its partnership with Lucentis in the three-month Phase...

  • Ophthotech Quickly Snares $36M And 2 AMD Licenses. Young, Donna // BioWorld Today;8/14/2007, Vol. 18 Issue 157, p1 

    The article focuses on the newly formed company Ophthotech established by former Eyetech co-founders David R. Guyer and Samir Patel. The company announced Series A financing of $36 million and two in-licensing deals for compounds for age-related macular degeneration (AMD). The round of financing...

  • TargeGen Advances AMD Program With $40M.  // Bioworld Week;7/23/2007, Vol. 15 Issue 30, p2 

    The article reports that TargeGen Inc. closed Series D financing round, which raised $40 million that will be used to fund the upcoming Phase II development of its lead program in the U.S. The company's lead program is an eye drop for treating macular degeneration and other back-of-the-eye...

  • OPHTHOTECH. Investor's Business Daily // Investors Business Daily;5/20/2014, pA02 

    The article reports that biotechnology company Ophthotech licensed its Fovista macular degeneration drug to pharmaceutical company Novartis AG and mentions the increase of Ophthotech's shares and decline in Novartis' shares.

  • MethylGene Pulls in $35M for Cancer, Antifungal Work.  // Bioworld Week;3/28/2011, Vol. 19 Issue 13, p1 

    The article reports on the disclosure of a 35.3 million U.S. dollars financing to boost the work of Montreal, Quebec-based MethylGene Inc.'s programs in cancer and fungal infections on March 24, 2011. It states that the net proceeds of the financing will be used to push its two lead programs...

  • Revisioning AMD: 'All Wet' Therapies Hung Out to Dry? Osborne, Randy // BioWorld Insight;5/3/2010, Vol. 18 Issue 18, p1 

    The article reports that Ophthotech Corp.'s Phase II trial with the aptamer E10030 as combination therapy used with Lucentis still depicted more attention to wet age-related macular degeneration (AMD). More common dry form of AMD is start up ReVision Therapeutics Inc. with fenretinide, known as...

  • Meet Your Next AMD Drug. Bethke, Walter // Review of Ophthalmology;Aug2015, Vol. 22 Issue 8, p38 

    The article offers brief information on several age-related macular degeneration drugs including Fovista from Ophthotech, Lampalizumab from Roche and Squalamine Lactate from Ohr Pharmaceutical.

  • Anti-PDGF found safe. Krader, Cheryl Guttman; Ho, Allen C. // Ophthalmology Times;4/15/2010, Vol. 35 Issue 8, p44 

    The article discusses the result of the phase I clinical study of Ophthotec's E10030 anti-platelet-derived growth factor aptamer for the treatment of neovascular age-related macular degeneration (AMD). It was found that E10030 is well-tolerated when used with anti-vascular endothelial growth...

  • Ophthotech's Novel Anti-PDGF Combination Agent FovistaTM Demonstrated Superior Efficacy over Lucentis(r) Monotherapy in Large Controlled Wet AMD Trial.  // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1 

    The article focuses on the Phase 2b clinical trial of Ophthotech Corp.'s Fovista anti-PDGF therapy, administered in combination with Lucentis anti-VEGF therapy in patients with neovascular age-related macular degeneration (wet AMD). The study showed that treatment was significantly efficient...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics